retatrutide ly3437943 triple agonist glp-1 gip glucagon mechanism (LY3437943): of Action and Research Overview LY3437943, a novel triple glucagon,

Popular branded versions include: Ozempic (semaglutide) : Approved for Type 2 diabetes Wegovy (semaglutide) : Approved for chronic weight management Mounjaro (tirzepatide) : Newer dual-action drug also making waves GLP-1 drugs are typically injected weekly and have been shown to reduce blood sugar levels and body weight dramatically

These drugs are available as a daily or weekly injection or a daily pill

Nat Rev Endocrinol (2018) 14(5):27084

Adding another GLP-1 agonist does not increase efficacy

Tirzepatide Once Weekly for the Treatment of Obesity AMG 133 is a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule

doi: 10.1001/jamacardio.2018.0022 20 GuhDPZhangWBansbackNAmarsiZBirminghamCLAnisAH